Skip to main content

Table 1 Characteristics of HBsAg-positive pregnant women who underwent fetal blood sampling and outcomes of infants

From: Risk of mother-to-child transmission of hepatitis B virus after fetal blood sampling: a report of six cases

Characteristics and Outcomes Case series
CASE 1 CASE 2 CASE 3 CASE 4 CASE 5 CASE 6
Mothers
 Maternal age, years 27 26 30 34 35 28
 Gravida/Parity 1/1 1/1 1/1 5/2 3/3 1/1
 Antiviral therapy No Yesa No No No No
 HBeAg status Positive Positive Negative Negative Negative Negative
 Baseline HBV DNA levels, log10 IU/ml 7.48 4.52 Undetected Undetected 2.51 2.52
 Mode of delivery Vaginal delivery Vaginal delivery Vaginal delivery Caesarean section Vaginal delivery Vaginal delivery
 Gestational weeks at delivery 39+ 5 41 39+ 4 39+ 2 32+ 1 38+ 3
 Obstetric complications No No No No Preterm birth No
FBS Technique
 Gestational weeks 26+ 2 32+ 4 31+ 3 32+ 4 29+ 2 25+ 3
 Indications Ventricular septal defect Ventriculomegaly Suboccipital cystic mass Fetal growth restriction Hydronephrosis Ventricular septal defect
 Transplacental penetration Yes No No No No No
 Post-procedure bleeding (from placenta or uterine wall) Yes No No No No No
 Post-procedure streaming (from punctured umbilical cord) Yes Yes Yes Yes Yes Yes
Infants
 Sex Male Male Male Male Female Female
 Birthweight, gram 3100 2950 3200 2600 1900 3400
 HBsAg status at birth Positive Negative Negative Negative Negative Negative
 Timing of Follow-up, months 12 12 29 32 12 38
 HBsAg status at the end of follow-up Positive Negative Negative Negative Negative Negative
 Anti-HBs status at the end of follow-up Negative Positive Positive Positive Positive Positive
  1. aTenofovir disoproxil fumarate 300 mg daily from 26+ 3 weeks of gestation to postpartum week 4